Inventprise develops high-valent vaccines using a proprietary linker platform, with an initial focus on invasive pneumococcal disease. Its lead candidate, IVT-25, is a 25-valent pneumococcal conjugate vaccine designed to target key strains causing invasive disease in children, particularly in low- and middle-income countries. Preclinical head-to-head studies reportedly show IVT-25 superiority to currently licensed vaccines. The company plans first-in-human clinical trials for IVT-25 in the second half of 2022 and aims to complete Phase 1 and Phase 2 studies to demonstrate safety and immunological proof-of-concept. Inventprise also has a pipeline including candidates for HPV, group B streptococcus, meningococcus and SARS-CoV-2. The company has committed to making IVT-25 available and affordable to low- and middle-income countries and to make its platform available for future global-health vaccines.

Total raised

$90M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2021